Monday, October 3, 2022


Biotechnology News Magazine

Diamyd Medical Reports New meta-analysis with Diamyd® Published in Diabetes, Obesity and Metabolism

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Diamyd Medical: An update of a large-scale meta-analysis supporting the efficacy of the therapeutic diabetes vaccine Diamyd® in individuals recently diagnosed with Type 1 Diabetes carrying the genetic HLA DR3-DQ2 haplotype has been published in the peer-reviewd scientific journal Diabetes, Obesity and Metabolism.

Diamyd Medical notes the analysis shows that treatment effect with Diamyd® on the preservation of endogenous insulin production measured as C-peptide is associated with a beneficial treatment effect on blood glucose measured as HbA1c.

“To our knowledge, this is the first analysis that shows a clear association between positive treatment effects on C-peptide and blood glucose control in this patient population, providing further support for the clinical efficacy of the diabetes vaccine Diamyd in the genetic target population of Type 1 Diabetes patients with HLA DR3-DQ2, says Christoph Nowak, MD PhD, Medical & Data Officer at Diamyd Medical and first author of the recently published article. “The association also lends further support to the importance of C-peptide as a clinically meaningful surrogate endpoint in clinical trials, and strengthens our confidence in the primary endpoints of C-peptide and HbA1c in the confirmatory phase 3 trial DIAGNODE-3.

“These data are very important for the field of Type 1 Diabetes, supporting the clinical rationale of disease-modifying treatments that focus on preserving the individual’s own insulin production”, says Johnny Ludvigsson, Professor at Linköping University and senior author of the article.

The analysis is based on data from more than 600 individuals who participated in four placebo-controlled randomized clinical trials evaluating the effect of the therapeutic diabetes vaccine Diamyd® on preserving endogenous insulin production. The results support the notion that preservation of C-peptide using Diamyd® vaccine correlates with beneficial effects on HbA1c in individuals with recent-onset Type 1 Diabetes carrying the genetic haplotype HLA DR3-DQ2 and receiving standard of care diabetes treatment.

The article is published online in Diabetes, Obesity and Metabolism, a journal currently ranked 21st out of 145 in the Endocrine category, and can be accessed at

The article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between the version available as of April 20, 2022, and the final version. A freely accessible Open Access version of the final article is expected to become available shortly.

About Diamyd Medical: Diamyd Medical develops precision medicine therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a large genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes.

DIAGNODE-3, a confirmatory Phase III trial is on-going. A vaccine manufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®.

Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia.

An investigator-initiated Remygen® trial in individuals living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB as well as in the artificial intelligence company MainlyAI AB.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine